Male Breast Cancer: Three Case Reports and a Literature Review


Cite item

Full Text

Abstract

Introduction:Male breast cancer (MBC) accounts for 0.5%-1% of all breast cancers diagnosed worldwide. However, its biological characteristics can be distinguished from that of female breast cancer (FBC)

Case Representation:The diagnostic and treatment approaches for MBC are mainly similar to that of FBC due to the lack of male breast cancer-related studies, clinical trials, and literature. An increasing number of retrospective and prospective studies have been conducted to clarify the individualized care for MBC. Herein, we report three cases of advanced MBC to describe the diagnostic approaches, treatment process, and survival prognosis.

Conclusion: MBC patients had older age, later stage at first diagnosis, higher expression of hormone receptors, and poor prognosis. A literature review was conducted to determine the incidence, risk factors, disease features, diagnosis, treatment, survival, and management of MBC.

About the authors

Yuanfang Xin

, Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University

Email: info@benthamscience.net

Fengmei Wang

Pathology Department of Affiliated Hospital, Qinghai University and Affiliated Cancer Hospital of Qinghai University

Email: info@benthamscience.net

Dengfeng Ren

, Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University

Email: info@benthamscience.net

Fuxing Zhao

, Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University

Email: info@benthamscience.net

Jiuda Zhao

, Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University and Affiliated Cancer Hospital of Qinghai University

Author for correspondence.
Email: info@benthamscience.net

References

  1. Reis, L.O.; Dias, F.G.; Castro, M.A.; Ferreira, U. Male breast cancer. Aging Male, 2011, 14(2), 99-109. doi: 10.3109/13685538.2010.535048 PMID: 21204612
  2. Abdelwahab Yousef, A.J. Male breast cancer: Epidemiology and risk factors. Semin. Oncol., 2017, 44(4), 267-272. doi: 10.1053/j.seminoncol.2017.11.002 PMID: 29526255
  3. Gucalp, A.; Traina, T.A.; Eisner, J.R.; Parker, J.S.; Selitsky, S.R.; Park, B.H.; Elias, A.D.; Baskin-Bey, E.S.; Cardoso, F. Male breast cancer: A disease distinct from female breast cancer. Breast Cancer Res. Treat., 2019, 173(1), 37-48. doi: 10.1007/s10549-018-4921-9 PMID: 30267249
  4. Comparison between male and female breast cancer survival using propensity score matching analysis. Available From: https://pubmed.ncbi.nlm.nih.gov/34079019/ (Accessed May 16 2022)
  5. Elbachiri, M.; Fatima, S.; Bouchbika, Z.; Benchekroun, N.; Jouhadi, H.; Tawfiq, N.; Sahraoui, S.; Benider, A. Breast cancer in men: About 40 cases and literature review. Pan Afr. Med. J., 2017, 28, 287. doi: 10.11604/pamj.2017.28.287.13527 PMID: 29675121
  6. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33. doi: 10.3322/caac.21654 PMID: 33433946
  7. Leon-Ferre, R.A.; Giridhar, K.V.; Hieken, T.J.; Mutter, R.W.; Couch, F.J.; Jimenez, R.E.; Hawse, J.R.; Boughey, J.C.; Ruddy, K.J. A contemporary review of male breast cancer: Current evidence and unanswered questions. Cancer Metastasis Rev., 2018, 37(4), 599-614. doi: 10.1007/s10555-018-9761-x PMID: 30232577
  8. Darkeh, M.H.S.E.; Azavedo, E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. Int. J. Clin. Med., 2014, 5(17), 1068-1086. doi: 10.4236/ijcm.2014.517138
  9. Anderson, W.F.; Jatoi, I.; Tse, J.; Rosenberg, P.S. Male breast cancer: A population-based comparison with female breast cancer. J. Clin. Oncol., 2010, 28(2), 232-239. doi: 10.1200/JCO.2009.23.8162 PMID: 19996029
  10. Miao, H.; Verkooijen, H.M.; Chia, K.S.; Bouchardy, C.; Pukkala, E.; Larønningen, S.; Mellemkjær, L.; Czene, K.; Hartman, M. Incidence and outcome of male breast cancer: An international population-based study. J. Clin. Oncol., 2011, 29(33), 4381-4386. doi: 10.1200/JCO.2011.36.8902 PMID: 21969512
  11. Scott-Conner, C.E.H.; Jochimsen, P.R.; Menck, H.R.; Winchester, D.J. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery, 1999, 126(4), 775-781. doi: 10.1016/S0039-6060(99)70135-2 PMID: 10520928
  12. Yalaza, M.; İnan, A.; Bozer, M. Male breast cancer. J. Breast Health, 2016, 12(1), 1-8. doi: 10.5152/tjbh.2015.2711 PMID: 28331724
  13. Fentiman, I.S.; Fourquet, A.; Hortobagyi, G.N. Male breast cancer. Lancet, 2006, 367(9510), 595-604. doi: 10.1016/S0140-6736(06)68226-3 PMID: 16488803
  14. Is male breast cancer similar or different than female breast cancer? Available From: https://pubmed.ncbi.nlm.nih.gov/14997057/ (Accessed November 18 2021)
  15. Agrawal, A.; Ayantunde, A.A.; Rampaul, R.; Robertson, J.F.R. Male breast cancer: A review of clinical management. Breast Cancer Res. Treat., 2007, 103(1), 11-21. doi: 10.1007/s10549-006-9356-z PMID: 17033919
  16. Giordano, S.H. Breast cancer in men. N. Engl. J. Med., 2018, 378(24), 2311-2320. doi: 10.1056/NEJMra1707939 PMID: 29897847
  17. Antoniou, A.; Pharoah, P.D.P.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, Å.; Pasini, B.; Radice, P.; Manoukian, S.; Eccles, D.M.; Tang, N.; Olah, E.; Anton-Culver, H.; Warner, E.; Lubinski, J.; Gronwald, J.; Gorski, B.; Tulinius, H.; Thorlacius, S.; Eerola, H.; Nevanlinna, H.; Syrjäkoski, K.; Kallioniemi, O.P.; Thompson, D.; Evans, C.; Peto, J.; Lalloo, F.; Evans, D.G.; Easton, D.F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet., 2003, 72(5), 1117-1130. doi: 10.1086/375033 PMID: 12677558
  18. Balcı, A.; Huusko, P.; Pääkkönen, K.; Launonen, V.; Üner, A.; Ekmekçi, A.; Winqvist, R. Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: A novel mutation BRCA2 3414del4 found in male breast cancer. Eur. J. Cancer, 1999, 35(5), 707-710. doi: 10.1016/S0959-8049(99)00014-3 PMID: 10505028
  19. Ottini, L.; Masala, G.; D'Amico, C.; Mancini, B.; Saieva, C.; Aceto, G.; Gestri, D.; Vezzosi, V.; Falchetti, M.; De Marco, M.; Paglierani, M.; Cama, A.; Bianchi, S.; Mariani-Costantini, R.; Palli, D. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: A population-based study in Italy. Cancer Res., 2003, 63(2), 342-347. PMID: 12543786
  20. Basham, V.M.; Lipscombe, J.M.; Ward, J.M.; Gayther, S.A.; Ponder, B.A.J.; Easton, D.F.; Pharoah, P.D.P. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res., 2001, 4(1), R2. doi: 10.1186/bcr419 PMID: 11879560
  21. Lenfant-Pejovic, M.H.; Mlika-Cabanne, N.; Bouchardy, C.; Auquier, A. Risk factors for male breast cancer: A Franco-Swiss case-control study. Int. J. Cancer, 1990, 45(4), 661-665. doi: 10.1002/ijc.2910450415 PMID: 2323842
  22. Olsson, H.; Ranstam, J. Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer. J. Natl. Cancer Inst., 1988, 80(9), 679-683. doi: 10.1093/jnci/80.9.679 PMID: 3373557
  23. De Los Santos, J.F.; Buchholz, T.A. Carcinoma of the male breast. Curr. Treat. Options Oncol., 2000, 1(3), 221-227. doi: 10.1007/s11864-000-0033-x PMID: 12057164
  24. Lowell, D.M.; Martineau, R.G.; Luria, S.B. Carcinoma of the male breast following radiation. Report of a case occurring 35 years after radiation therapy of unilateral prepubertal gynecomastia. Cancer, 1968, 22(3), 581-586. doi: 10.1002/1097-0142(196809)22:3<581:AID-CNCR2820220314>3.0.CO;2-N PMID: 4299779
  25. Sasco, A.J.; Lowenfels, A.B.; Jong, P.P-D. Review article: Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int. J. Cancer, 1993, 53(4), 538-549. doi: 10.1002/ijc.2910530403 PMID: 8436428
  26. Ron, E.; Ikeda, T.; Preston, D.L.; Tokuoka, S. Male breast cancer incidence among atomic bomb survivors. J. Natl. Cancer Inst., 2005, 97(8), 603-605. doi: 10.1093/jnci/dji097 PMID: 15840883
  27. Little, M.P.; McElvenny, D.M. Male breast cancer incidence and mortality risk in the japanese atomic bomb survivors: Differences in excess relative and absolute risk from female breast cancer. Environ. Health Perspect., 2017, 125(2), 223-229. doi: 10.1289/EHP151 PMID: 27286002
  28. Brainard, G.C.; Kavet, R.; Kheifets, L.I. The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: A review of the relevant literature. J. Pineal Res., 1999, 26(2), 65-100. doi: 10.1111/j.1600-079X.1999.tb00568.x PMID: 10100735
  29. Stenlund, C.; Floderus, B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: A Swedish case-control study. Cancer Causes Control, 1997, 8(2), 184-191. doi: 10.1023/A:1018468112964 PMID: 9134242
  30. Rosenbaum, P.F.; Vena, J.E.; Zielezny, M.A.; Michalek, A.M. Occupational exposures associated with male breast cancer. Am. J. Epidemiol., 1994, 139(1), 30-36. doi: 10.1093/oxfordjournals.aje.a116932 PMID: 8296772
  31. Sun, J.W.; Li, X.R.; Gao, H.Y.; Yin, J.Y.; Qin, Q.; Nie, S.F.; Wei, S. Electromagnetic field exposure and male breast cancer risk: A meta-analysis of 18 studies. Asian Pac. J. Cancer Prev., 2013, 14(1), 523-528. doi: 10.7314/APJCP.2013.14.1.523 PMID: 23534787
  32. Hansen, J. Elevated risk for male breast cancer after occupational exposure to gasoline and vehicular combustion products. Am. J. Ind. Med., 2000, 37(4), 349-352. doi: 10.1002/(SICI)1097-0274(200004)37:4<349:AID-AJIM4>3.0.CO;2-L PMID: 10706746
  33. Laouali, N.; Pilorget, C.; Cyr, D.; Neri, M.; Kaerlev, L.; Sabroe, S.; Gorini, G.; Richiardi, L.; Morales-Suárez-Varela, M.; Llopis-Gonzalez, A.; Ahrens, W.; Jöckel, K.H.; Afonso, N.; Eriksson, M.; Merletti, E.; Olsen, J.; Lynge, E.; Guénel, P. Occupational exposure to organic solvents and risk of male breast cancer: A European multicenter case-control study. Scand. J. Work Environ. Health, 2018, 44(3), 310-322. doi: 10.5271/sjweh.3717 PMID: 29405242
  34. Brinton, L.A.; Key, T.J.; Kolonel, L.N.; Michels, K.B.; Sesso, H.D.; Ursin, G.; Van Den Eeden, S.K.; Wood, S.N.; Falk, R.T.; Parisi, D.; Guillemette, C.; Caron, P.; Turcotte, V.; Habel, L.A.; Isaacs, C.J.; Riboli, E.; Weiderpass, E.; Cook, M.B. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J. Clin. Oncol., 2015, 33(18), 2041-2050. doi: 10.1200/JCO.2014.59.1602 PMID: 25964249
  35. Hultborn, R.; Hanson, C.; Köpf, I.; Verbiené, I.; Warnhammar, E.; Weimarck, A. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res., 1997, 17(6D), 4293-4297. PMID: 9494523
  36. Ruddy, K.J.; Winer, E.P. Male breast cancer: Risk factors, biology, diagnosis, treatment, and survivorship. Ann. Oncol., 2013, 24(6), 1434-1443. doi: 10.1093/annonc/mdt025 PMID: 23425944
  37. Giordano, S.H.; Cohen, D.S.; Buzdar, A.U.; Perkins, G.; Hortobagyi, G.N. Breast carcinoma in men. Cancer, 2004, 101(1), 51-57. doi: 10.1002/cncr.20312 PMID: 15221988
  38. Chavez-MacGregor, M.; Clarke, C.A.; Lichtensztajn, D.; Hortobagyi, G.N.; Giordano, S.H. Male breast cancer according to tumor subtype and race. Cancer, 2013, 119(9), 1611-1617. doi: 10.1002/cncr.27905 PMID: 23341341
  39. Cardoso, F.; Bartlett, J.M.S.; Slaets, L.; van Deurzen, C.H.M.; van Leeuwen-Stok, E.; Porter, P.; Linderholm, B.; Hedenfalk, I.; Schröder, C.; Martens, J.; Bayani, J.; van Asperen, C.; Murray, M.; Hudis, C.; Middleton, L.; Vermeij, J.; Punie, K.; Fraser, J.; Nowaczyk, M.; Rubio, I.T.; Aebi, S.; Kelly, C.; Ruddy, K.J.; Winer, E.; Nilsson, C.; Lago, L.D.; Korde, L.; Benstead, K.; Bogler, O.; Goulioti, T.; Peric, A.; Litière, S.; Aalders, K.C.; Poncet, C.; Tryfonidis, K.; Giordano, S.H. Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann. Oncol., 2018, 29(2), 405-417. doi: 10.1093/annonc/mdx651 PMID: 29092024
  40. Bagchi, S. Men with breast cancer have high risk of second cancer. Lancet Oncol., 2007, 8(3), 198. doi: 10.1016/S1470-2045(07)70067-0 PMID: 17348113
  41. Dong, C.; Hemminki, K. Second primary breast cancer in men. Breast Cancer Res. Treat., 2001, 66(2), 171-172. doi: 10.1023/A:1010639429207 PMID: 11437104
  42. Mathew, J.; Perkins, G.H.; Stephens, T.; Middleton, L.P.; Yang, W.T. Primary breast cancer in men: clinical, imaging, and pathologic findings in 57 patients. AJR Am. J. Roentgenol., 2008, 191(6), 1631-1639. doi: 10.2214/AJR.08.1076 PMID: 19020230
  43. Draghi, F.; Tarantino, C.C.; Madonia, L.; Ferrozzi, G. Ultrasonography of the male breast. J. Ultrasound, 2011, 14(3), 122-129. doi: 10.1016/j.jus.2011.06.004 PMID: 23397020
  44. Yitta, S.; Singer, C.I.; Toth, H.B.; Mercado, C.L. Image presentation. Sonographic appearances of benign and malignant male breast disease with mammographic and pathologic correlation. J. Ultrasound Med., 2010, 29(6), 931-947. doi: 10.7863/jum.2010.29.6.931 PMID: 20498468
  45. Sneige, N.; Holder, P.D.; Katz, R.L.; Fanning, C.V.; Dekmezian, R.H.; Shabb, N.S.; Singletary, S.E. Fine-needle aspiration cytology of the male breast in a cancer center. Diagn. Cytopathol., 1993, 9(6), 691-697. doi: 10.1002/dc.2840090619 PMID: 8143548
  46. Hoda, R.S.; Arpin, R.N., III; Gottumukkala, R.V.; Hughes, K.S.; Ly, A.; Brachtel, E.F. Diagnostic value of fine-needle aspiration in male breast lesions. Acta Cytol., 2019, 63(4), 319-327. doi: 10.1159/000494486 PMID: 30904908
  47. Yang, Y.; Li, S.; Liu, G.; Shao, Z. Is core needle biopsy effective at diagnosing male breast lesions? Breast Cancer Res. Treat., 2019, 177(2), 507-511. doi: 10.1007/s10549-019-05312-x PMID: 31168757
  48. Massarweh, S.A.; Sledge, G.W.; Miller, D.P.; McCullough, D.; Petkov, V.I.; Shak, S. Molecular characterization and mortality from breast cancer in men. J. Clin. Oncol., 2018, 36(14), 1396-1404. doi: 10.1200/JCO.2017.76.8861 PMID: 29584547
  49. Turashvili, G.; Gonzalez-Loperena, M.; Brogi, E.; Dickler, M.; Norton, L.; Morrow, M.; Wen, H.Y. The 21-gene recurrence score in male breast cancer. Ann. Surg. Oncol., 2018, 25(6), 1530-1535. doi: 10.1245/s10434-018-6411-z PMID: 29520654
  50. Grenader, T.; Yerushalmi, R.; Tokar, M.; Fried, G.; Kaufman, B.; Peretz, T.; Geffen, D.B. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: Experience in an Israeli cohort. Oncology, 2014, 87(1), 1-6. doi: 10.1159/000360793 PMID: 24970679
  51. La Pinta, M.; Fabi, A.; Ascarelli, A.; Ponzani, T.; Di Carlo, V.; Scicchitano, F.; Saputo, S.; Russillo, M.; Andrich, R. Male breast cancer: 6-year experience. Minerva Chir., 2008, 63(2), 71-78. PMID: 18427439
  52. Lin, A.P.; Huang, T.W.; Tam, K.W. Treatment of male breast cancer: meta-analysis of real-world evidence. Br. J. Surg., 2021, 108(9), 1034-1042. doi: 10.1093/bjs/znab279 PMID: 34476472
  53. Yadav, S.; Karam, D.; Bin Riaz, I.; Xie, H.; Durani, U.; Duma, N.; Giridhar, K.V.; Hieken, T.J.; Boughey, J.C.; Mutter, R.W.; Hawse, J.R.; Jimenez, R.E.; Couch, F.J.; Leon-Ferre, R.A.; Ruddy, K.J. Male breast cancer in the united states: Treatment patterns and prognostic fac-tors in the 21st century. Cancer, 2020, 126(1), 26-36. doi: 10.1002/cncr.32472 PMID: 31588557
  54. Rogowski, P.; Schönecker, S.; Pazos, M.; Reitz, D.; Braun, M.; Pölcher, M.; Hanusch, C.; Wuerstlein, R.; Harbeck, N.; Mahner, S.; Belka, C.; Corradini, S. Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: An observational study. Strahlenther. Onkol., 2019, 195(4), 289-296. doi: 10.1007/s00066-018-1337-8 PMID: 30046931
  55. Jardel, P.; Vignot, S.; Cutuli, B.; Creisson, A.; Vass, S.; Barranger, E.; Thariat, J. Should adjuvant radiation therapy be systematically pro-posed for male breast cancer? a systematic review. Anticancer Res., 2018, 38(1), 23-31. doi: 10.21873/anticanres.12187 PMID: 29277752
  56. Onkologie, L. S3-leitlinie früherkennung, diagnose, therapie und nachsorge des mammakarzinoms, version 4.0, 2017 AWMF register-nummer: 032-045OL. Retrieved, 2018, 28, 198-201.
  57. Gennari, R.; Curigliano, G.; Jereczek-Fossa, B.; Zurrida, S.; Renne, G.; Intra, M.; Galimberti, V.; Luini, A.; Orecchia, R.; Viale, G.; Gold-hrisch, A.; Veronesi, U. Male breast cancer: A special therapeutic problem. Anything new? (Review). Int. J. Oncol., 2004, 24(3), 663-670. doi: 10.3892/ijo.24.3.663 PMID: 14767551
  58. Korde, L.A.; Zujewski, J.A.; Kamin, L.; Giordano, S.; Domchek, S.; Anderson, W.F.; Bartlett, J.M.S.; Gelmon, K.; Nahleh, Z.; Bergh, J.; Cutuli, B.; Pruneri, G.; McCaskill-Stevens, W.; Gralow, J.; Hortobagyi, G.; Cardoso, F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J. Clin. Oncol., 2010, 28(12), 2114-2122. doi: 10.1200/JCO.2009.25.5729 PMID: 20308661
  59. Yu, X.F.; Wang, C.; Chen, B.; Liang, C.; Chen, D.; Yu, Y.; Yang, H. The effect of adjuvant chemotherapy in male breast cancer: 134 Cases from a retrospective study. ESMO Open, 2017, 2(2), e000134. doi: 10.1136/esmoopen-2016-000134 PMID: 28761739
  60. Bagley, C.S.; Wesley, M.N.; Young, R.C.; Lippman, M.E. Adjuvant chemotherapy in males with cancer of the breast. Am. J. Clin. Oncol., 1987, 10(1), 55-60. doi: 10.1097/00000421-198702000-00013 PMID: 3825994
  61. Walshe, J.M.; Berman, A.W.; Vatas, U.; Steinberg, S.M.; Anderson, W.F.; Lippman, M.E.; Swain, S.M. A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res. Treat., 2007, 103(2), 177-183. doi: 10.1007/s10549-006-9363-0 PMID: 17039267
  62. Li, W.P.; Gao, H.F.; Ji, F.; Zhu, T.; Cheng, M.Y.; Yang, M.; Yang, C.Q.; Zhang, L.L.; Li, J.Q.; Zhang, J.S.; Wang, K. The role of adjuvant chemotherapy in stage I-III male breast cancer: A SEER-based analysis. Ther. Adv. Med. Oncol., 2020, 12. doi: 10.1177/1758835920958358 PMID: 33014148
  63. Hassett, M.J.; Somerfield, M.R.; Baker, E.R.; Cardoso, F.; Kansal, K.J.; Kwait, D.C.; Plichta, J.K.; Ricker, C.; Roshal, A.; Ruddy, K.J.; Safer, J.D.; Van Poznak, C.; Yung, R.L.; Giordano, S.H. Management of male breast cancer: ASCO guideline. J. Clin. Oncol., 2020, 38(16), 1849-1863. doi: 10.1200/JCO.19.03120 PMID: 32058842
  64. Eggemann, H.; Brucker, C.; Schrauder, M.; Thill, M.; Flock, F.; Reinisch, M.; Costa, S.D.; Ignatov, A. Survival benefit of tamoxifen in male breast cancer: Prospective cohort analysis. Br. J. Cancer, 2020, 123(1), 33-37. doi: 10.1038/s41416-020-0857-z PMID: 32367072
  65. Eggemann, H.; Altmann, U.; Costa, S.D.; Ignatov, A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J. Cancer Res. Clin. Oncol., 2018, 144(2), 337-341. doi: 10.1007/s00432-017-2539-7 PMID: 29098396
  66. Fentiman, I.S. The endocrinology of male breast cancer. Endocr. Relat. Cancer, 2018, 25(6), R365-R373. doi: 10.1530/ERC-18-0117 PMID: 29752333
  67. Visram, H.; Kanji, F.; Dent, S.F. Endocrine therapy for male breast cancer: Rates of toxicity and adherence. Curr. Oncol., 2010, 17(5), 17-21. doi: 10.3747/co.v17i5.631 PMID: 20975874

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bentham Science Publishers